Heartflow, Inc. (HTFL) Stock Price & Analysis

Heartflow, Inc. (HTFL) fell 2.37% to USD 47.75 as of September 9, 2026 at 11:42 UTC, according to Nexqual real-time market data.

HTFL last closed at USD 47.75; the session ranged USD 47.14–50.17 on volume of 2,804,622 shares. Market capitalization is —, with a 52-week range of USD 20.13–51.78 (NMS). Source: Nexqual, September 9, 2026 at 11:42 UTC.

Key Statistics (as of September 9, 2026 at 11:42 UTC)

Technical Analysis (HTFL)

Nexqual's technical model rates HTFL "BUY" based on 5 bullish and 1 bearish signals across 127 daily candles, as of September 9, 2026 at 11:42 UTC.

From Heartflow, Inc.'s Latest SEC 10-K Filing (filed 2026-03-18)

Key Strengths & Strategy (as disclosed to the SEC)

• Our Data Security Our Heartflow Platform relies on industry-leading security controls, including encryption at rest and in transit, multi-factor and single-sign on authentication, granular authorization and a secure development lifecycle.
• Our clinical studies, including the PRECISE, NXT and PACIFIC trials, have consistently demonstrated that the Heartflow Platform is more accurate than traditional non-invasive tests and highly concordant to invasive testing, reduces unnecessary invasive testing, and enables physicians to optimize treatment and ultimately provide more efficient care.
• Our studies, including the PRECISE, NXT and PACIFIC trials, have consistently demonstrated that the Heartflow Platform is more accurate than traditional non-invasive tests and highly concordant to invasive testing, reduces unnecessary invasive testing, and enables physicians to optimize treatment and ultimately provide more efficient care.
• Intellectual Property Our success depends in part on our ability to obtain, maintain and defend our patent and other proprietary rights for the Heartflow Platform, the validity and enforceability of our patents, our ability to operate without infringing the valid and enforceable patents and proprietary rights of third parties and the continued confidentiality of our know-how and trade secrets.

Partnerships

• The study showed that Heartflow's Plaque Analysis results for total plaque volume, calcified plaque, and non-calcified plaque were strongly correlated with IVUS measurements, achieving 95% agreement with IVUS. • DECODE (2024): Our Company-sponsored DECODE study evaluated the impact of the Heartflow Plaque Analysis on clinical decision-making using data from 100 patients who underwent CCTA.
• The Heartflow Plaque Analysis has been validated against the reference standard of invasive IVUS and shown to have a 95% agreement with IVUS in quantifying total coronary plaque volume in our REVEALPLAQUE study.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 9, 2026 at 11:42 UTC. This page is informational and not investment advice.